Medacta Group

Medacta Group EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Medacta Group (MOVE.SW) as of Oct 22, 2026 is 126.73. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 1,537.27 — a change of -91.76% (lower).

EV/FCF

126.73

YoY

-91.76%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Medacta Group is 2025 126.73 . EV/FCF (Enterprise Value to Free Cash Flow) of Medacta Group was 2024 1,537.27 . It decreases by -91.76% lower compared to the previous year.

The Medacta Group EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
327.18 EUR
Jan 1, 2019
3,173.71 EUR
Jan 1, 2020
113.34 EUR
Jan 1, 2021
485.08 EUR
Jan 1, 2022
357.20 EUR
Jan 1, 2023
-527.41 EUR
Jan 1, 2024
1,537.27 EUR
Jan 1, 2025
126.73 EUR
The Medacta Group EV/FCF history
YEAREV/FCFYoY
126.73-91.76%
1,537.27-391.47%
-527.41-247.65%
357.20-26.36%
485.08+327.98%
113.34-96.43%
3,173.71+870.02%
327.18+3.35%
316.56+147.75%
127.77—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medacta Group Stock analysis

What does Medacta Group do? The Medacta Group SA is a leading global company in the development, manufacturing, and marketing of medical devices and implants for the orthopedic industry. The company was founded in 1999 by Swiss entrepreneur Alberto Siccardi and is headquartered in Switzerland. The Medacta Group SA has its origins in one person - Alberto Siccardi. As a former athlete and successful entrepreneur, he had a vision that he put into action. He founded the Medacta Group and began focusing on the development and manufacturing of innovative orthopedic devices and implants. The Medacta Group has an innovative business model because the company is able to handle everything from research and development to marketing and sales of its products. This means that Medacta combines all steps from idea to end product under one roof and has complete control over the entire process. The Medacta Group SA is divided into three business areas: orthopedics, spine, and sports medicine. In the orthopedic field, the company manufactures hip and knee joint implants, as well as shoulder and elbow implants. Medacta also offers technologies that help extend the lifespan of artificial joints. In the spine field, the company provides instruments and implants for spine surgery. Medacta has a high level of expertise in this field and is known for innovative products that contribute to improving patient treatment. In the sports medicine field, the Medacta Group offers solutions for sports injuries. The company has developed a wide range of technologies and products that accelerate the healing process and support rehabilitation. Some of Medacta's most well-known products are the AMIS (Anterior Minimally Invasive Surgery) hip joint system and the GMK (General Medacta Knee) knee joint system. The AMIS system is a minimally invasive procedure for hip joint surgery that aims to shorten rehabilitation time and reduce the risk of complications. The GMK system is an innovative knee joint system that allows natural joint mechanics and approximates the natural knee pivot point. Medacta has also developed a range of software solutions that support surgeons in the planning and execution of operations. These solutions provide detailed visualizations and allow for precise planning of procedures. In conclusion, the Medacta Group SA is a global leader in the development and manufacturing of medical devices and implants for orthopedics, spine, and sports medicine. The company has an innovative business model that allows for complete control of the entire manufacturing process. Through the development of innovative products and technologies, the Medacta Group supports the treatment and rehabilitation of patients worldwide. Medacta Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medacta Group stock

EV/FCF (Enterprise Value to Free Cash Flow) of Medacta Group is 126.73 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Medacta Group changed from 1,537.27 to 126.73, representing a -91.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Medacta Group since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Medacta Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medacta Group

All Key Metrics — Medacta Group